Spectrum Pharmaceuticals Highlights 19 Abstracts at the 54th Annual Meeting of the American Society of Hematology (ASH …

HENDERSON, Nev.--(BUSINESS WIRE)--

Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data at the 54th Annual Meeting of the American Society of Hematology (ASH), being held in Atlanta, Georgia, from December 8-11, 2012. The presentations include two oral presentations and 10 poster presentations for ZEVALIN (ibritumomab tiuxetan) injection for intravenous use, three poster presentations for FOLOTYN (pralatrexate injection), and four poster presentations for belinostat, a novel histone deacetylase (HDAC) inhibitor.

Nearly 20 presentations at ASH will feature clinical and scientific data for Spectrums commercial products, ZEVALIN and FOLOTYN, as well as our late-stage drug candidate, belinostat, said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. The ZEVALIN-related abstracts demonstrate its use in a multitude of diverse settings and potential indications in which this product is being tested, including transplantation, its use in elderly patients, in frontline treatment and in the treatment of relapsed/refractory disease, as well as in new drug combinations. The FOLOTYN-related abstracts include presentations on new, synergistic combinations with other approved agents and in difficult-to-treat indications, such as HTLV-1-induced leukemia/lymphoma, while belinostat-related presentations are studying new combinations and indications, such as in refractory AML/MDS, as well as research on this promising drug candidates mechanism of action.

For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference Web site at https://ash.confex.com/ash/2012/webprogram/start.html.

The following are key ZEVALIN-related abstracts being presented at the ASH meeting:

Location

5:30 PM-7:30 PM

Hall B1-B2

6:00 PM-8:00 PM

Read the original here:
Spectrum Pharmaceuticals Highlights 19 Abstracts at the 54th Annual Meeting of the American Society of Hematology (ASH ...